In summary, our investigations revealed a critical role of STAT3 activation in COL1+ CAFs, suggesting that targeting of STAT3 in type I collagen-expressing fibroblasts could represent a promising therapeutic strategy in colitis-associated CRC and possibly other tumor entities. Here, STAT3 is linked to neoplasm.